PortfoliosLab logoPortfoliosLab logo
BTAI vs. EPR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

BTAI vs. EPR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BioXcel Therapeutics, Inc. (BTAI) and EPR Properties (EPR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BTAI achieves a -27.50% return, which is significantly lower than EPR's 16.06% return.


BTAI

1D
-2.52%
1M
-7.94%
YTD
-27.50%
6M
-39.27%
1Y
-15.33%
3Y*
-84.35%
5Y*
-70.94%
10Y*

EPR

1D
-0.21%
1M
2.52%
YTD
16.06%
6M
11.09%
1Y
6.73%
3Y*
16.78%
5Y*
8.98%
10Y*
3.54%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BTAI vs. EPR - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
BTAI
BioXcel Therapeutics, Inc.
-27.50%-73.25%-87.33%-86.27%5.66%-56.00%216.22%278.50%-65.00%
EPR
EPR Properties
16.06%20.52%-1.25%38.83%-14.61%50.60%-52.09%17.13%19.94%

Correlation

The correlation between BTAI and EPR is 0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.04

Correlation (3Y)
Calculated over the trailing 3-year period

0.14

Correlation (5Y)
Calculated over the trailing 5-year period

0.21

Correlation (All Time)
Calculated using the full available price history since Mar 9, 2018

0.15

The correlation between BTAI and EPR shifts across timeframes, from 0.04 (1 year) to 0.21 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

BTAI:

$27.34M

EPR:

$4.31B

EPS

BTAI:

-$5.21

EPR:

$3.55

PS Ratio

BTAI:

24.66

EPR:

6.16

Total Revenue (TTM)

BTAI:

$680.00K

EPR:

$700.22M

Gross Profit (TTM)

BTAI:

$175.00K

EPR:

$568.77M

EBITDA (TTM)

BTAI:

-$61.68M

EPR:

$582.57M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BTAI vs. EPR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BTAI
BTAI Risk / Return Rank: 4242
Overall Rank
BTAI Sharpe Ratio Rank: 3636
Sharpe Ratio Rank
BTAI Sortino Ratio Rank: 5353
Sortino Ratio Rank
BTAI Omega Ratio Rank: 5050
Omega Ratio Rank
BTAI Calmar Ratio Rank: 3535
Calmar Ratio Rank
BTAI Martin Ratio Rank: 3737
Martin Ratio Rank

EPR
EPR Risk / Return Rank: 4747
Overall Rank
EPR Sharpe Ratio Rank: 5151
Sharpe Ratio Rank
EPR Sortino Ratio Rank: 4343
Sortino Ratio Rank
EPR Omega Ratio Rank: 4242
Omega Ratio Rank
EPR Calmar Ratio Rank: 4848
Calmar Ratio Rank
EPR Martin Ratio Rank: 4848
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BTAI vs. EPR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BioXcel Therapeutics, Inc. (BTAI) and EPR Properties (EPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


BTAIEPRDifference
Sharpe ratioReturn per unit of total volatility

-0.41

Sortino ratioReturn per unit of downside risk

+0.43

Omega ratioGain probability vs. loss probability

1.11

1.07

+0.04

Calmar ratioReturn relative to maximum drawdown

-0.18

0.35

-0.53

Martin ratioReturn relative to average drawdown

-0.24

0.69

-0.93

BTAI vs. EPR - Sharpe Ratio Comparison

The current BTAI Sharpe Ratio is -0.11, which is lower than the EPR Sharpe Ratio of 0.30. The chart below compares the historical Sharpe Ratios of BTAI and EPR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


BTAIEPRDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.11

0.30

-0.41

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.59

0.35

-0.93

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.08

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.39

0.30

-0.69

Drawdowns

BTAI vs. EPR - Drawdown Comparison

The maximum BTAI drawdown since its inception was -99.90%, which is greater than EPR's maximum drawdown of -82.02%. Use the drawdown chart below to compare losses from any high point for BTAI and EPR.


Loading charts...

Drawdown Indicators


BTAIEPRDifference

Max Drawdown

Largest peak-to-trough decline

-99.90%

-82.02%

-17.88%

Max Drawdown (1Y)

Largest decline over 1 year

-85.00%

-19.51%

-65.49%

Max Drawdown (3Y)

Largest decline over 3 years

-99.70%

-19.51%

-80.19%

Max Drawdown (5Y)

Largest decline over 5 years

-99.84%

-35.63%

-64.21%

Max Drawdown (10Y)

Largest decline over 10 years

-82.02%

Current Drawdown

Current decline from peak

-99.89%

-5.28%

-94.61%

Average Drawdown

Average peak-to-trough decline

-63.19%

-16.60%

-46.59%

Ulcer Index

Depth and duration of drawdowns from previous peaks

64.43%

9.80%

+54.63%

Volatility

BTAI vs. EPR - Volatility Comparison

BioXcel Therapeutics, Inc. (BTAI) has a higher volatility of 18.08% compared to EPR Properties (EPR) at 5.07%. This indicates that BTAI's price experiences larger fluctuations and is considered to be riskier than EPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BTAIEPRDifference

Volatility (1M)

Calculated over the trailing 1-month period

18.08%

5.07%

+13.01%

Volatility (6M)

Calculated over the trailing 6-month period

55.78%

16.34%

+39.44%

Volatility (1Y)

Calculated over the trailing 1-year period

143.82%

22.25%

+121.57%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

121.38%

26.16%

+95.22%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

117.95%

42.44%

+75.51%

Dividends

BTAI vs. EPR - Dividend Comparison

BTAI has not paid dividends to shareholders, while EPR's dividend yield for the trailing twelve months is around 6.36%.


PositionTTM20252024202320222021202020192018201720162015
BTAI
BioXcel Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EPR
EPR Properties
6.36%7.05%7.68%6.81%8.62%3.16%4.66%6.37%5.62%6.23%5.35%6.21%

Financials

BTAI vs. EPR - Financials Comparison

This section allows you to compare key financial metrics between BioXcel Therapeutics, Inc. and EPR Properties. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M20222023202420252026
206.00K
181.25M
(BTAI) Total Revenue
(EPR) Total Revenue
Values in USD except per share items

Frequently Asked Questions


BTAI and EPR have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BTAI has higher volatility (18.08%) compared to EPR (5.07%). In terms of maximum drawdown, BTAI dropped -99.90% vs EPR's -82.02%.

EPR currently has the higher Sharpe Ratio (0.30 vs -0.11), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BTAI and EPR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer